CLEA Japan Academic Presentation Archive：Keystone Symposia 2026

2026/04/08

Cardiovascular–Kidney–Metabolic Nexus

In this presentation, we will introduce SDT fatty/Jcl and discuss its conceptual positioning within the CKM framework, with a particular focus on its relevance to integrated cardiovascular, renal, and metabolic research. The poster will highlight the model’s fundamental research potential and its applicability in studies involving emerging therapeutic approaches, including GLP-1 receptor agonists such as semaglutide.

Through this contribution, we aim to support ongoing scientific dialogue in the CKM field and provide researchers with insights into how SDT fatty/Jcl can be utilized as a translational model in this evolving research area.

Key Word：
Cardiovascular–Kidney–Metabolic (CKM), Semaglutide, GLP-1 Receptor Agonist